Citation Impact
Citing Papers
Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management
2010
Biologic Drugs for the Treatment of Hidradenitis Suppurativa: An Evidence-Based Review
2010
Deciphering the Clinical Presentations, Pathogenesis, and Treatment of the Idiopathic Inflammatory Myopathies
2011
An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features
2015 Standout
Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa
2011 Standout
Definitions and Diagnosis of Pulmonary Hypertension
2013 Standout
Exercise Standards for Testing and Training
2013 Standout
The natural history of progressive fibrosing interstitial lung diseases
2019
Borderline Pulmonary Arterial Pressure Is Associated with Decreased Exercise Capacity in Scleroderma
2009
Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo‐phase trial
2012
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
Treatment of Hidradenitis Suppurativa with Tumour Necrosis Factor-alpha Inhibitors
2009
Cardiopulmonary exercise testing in the assessment of pulmonary hypertension
2011
Hidradenitis suppurativa
2020 Standout
Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β
2011 Standout
Cutaneous Dermatomyositis: An Updated Review of Treatment Options and Internal Associations
2013
European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa
2015 Standout
Inflammatory Muscle Diseases
2015 Standout
Association of pyrin mutations and autoinflammation with complex phenotype hidradenitis suppurativa: a case–control study
2018
Review: Immune‐mediated necrotizing myopathies – a heterogeneous group of diseases with specific myopathological features
2012
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
2019 Standout
Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa
2012 Standout
Works of Daniel Sánchez‐Cano being referenced
Amyloidosis secondary to hidradenitis suppurativa. Exceptional response to infliximab
2008
Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group
2018
Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report of 4 cases and review of the literature.
2010
Prevalence of exercise pulmonary arterial hypertension in scleroderma.
2008